Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
OwnerRoland Buelowinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical preparations and methods for alleviating and reducing the gastrointestinal toxicity and dysfunction induced by cytoablative therapy, wherein immunomodulatory peptides are employed either alone or in combination with additional therapeutic agents. Also provided are improvements to cytoablative cancer therapy, wherein administration of the subject peptides in conjunction with cytoablative therapy enables the administration of increased maximum tolerated doses of the cytoablative agent(s) for improved efficacy and tumor response.
Claims18
A method for reducing the gastrointestinal toxicities induced by cytoablative therapy, comprising administering to a patient undergoing cytoablative therapy a pharmaceutically effective amount of an immunomodulatory peptide, wherein said immunomodulatory peptide comprises an oligopetide comprising the amino acid sequence
- B-X-X-X-B-X-X-X-J-Tyr
- wherein
- B is Lys or Arg;
- X is a aliphatic or aromatic amino acid;
- J is Gly, Lys or Arg,
- wherein said amino acids are the naturally occurring L-isomers, their D-isomers, and norleucine.
A pharmaceutical preparation for reducing gastrointestinal toxicity induced by cytoablative therapy, comprising:
- a) an oligopeptide comprising the sequence
- Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr
- wherein nL is norleucine and all amino acids are the D-stereoisomers;
- and
- b) at least one additional therapeutic agent selected from the group consisting of anti-diarrheal agents, anti-inflammatory agents and analgesics.
A method for improving cytoablative cancer therapy, comprising the administration of an increased maximum tolerated dose of a cytoablative agent in combination with a pharmaceutically effective amount of an immunomodulatory peptide, wherein said immunomodulatory peptide comprises an oligopetide comprising the amino acid sequence
- B-X-X-X-B-X-X-X-J-Tyr
- wherein
- B is Lys or Arg;
- X is a aliphatic or aromatic amino acid;
- J is Gly, Lys or Arg,
- wherein said amino acids are the naturally occurring L-isomers, their D-isomers, and norleucine.
Dependencies are inferred from the claim text.